Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy Virtual 2020 | COMy 2020 – what can we look forward to?

Artur Jurczyszyn • 11 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Belantamab mafodotin CAR-T

Artur Jurczyszyn, MD, PhD, Jagiellonian University Medical College, Kraków, Poland, highlights the data he’s looking forward to hearing at COMy 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Artur Jurczyszyn

Aims & projects of the Myeloma Treatment Foundation Centre in Poland 2:20
Aims & projects of the Myeloma Treatment Foundation Centre in Poland
Artur Jurczyszyn • 26 Aug 2022
The impact of physical activity in patients with multiple myeloma 1:21
The impact of physical activity in patients with multiple myeloma
Artur Jurczyszyn • 26 Aug 2022
The importance of early treatment in MGRS & the role of the MDT 1:25
The importance of early treatment in MGRS & the role of the MDT
Artur Jurczyszyn • 26 Aug 2022
The importance of bone disease control in multiple myeloma 1:13
The importance of bone disease control in multiple myeloma
Artur Jurczyszyn • 26 Aug 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals